Table 4.
Study | Treatment | No. p |
Sup % |
p | Criticism |
---|---|---|---|---|---|
GITSG 1982 | MeCCNU + 5FU | 71 | <0.03 | Not reproduced in | |
Control | 71 | VASOG y ECOG | |||
Neri et al 2001 | Epi + 5FU/LV | 69 | 30 | <0.01 | ? |
Control | 68 | 13 | |||
Grau et al 1998 | MMC | 45 | 44 | 0.004 | Small number of cases. |
MMC + tegafur | 40 | 67 | 11 years conscription. | ||
No control group | |||||
Hagiwara et al 1992 | IP carbon-absorbed | 24 | 69 | Small number of cases. | |
cisplatin | <0.005 | Australian study | |||
Control | 25 | 27 | negative. | ||
Kim et al 1992 | MMC + 5FU + AraC + OK432 | 74 | 45 | <0.05 | Small number of cases. |
Control | 64 | 23 | Not reproduced | ||
Cirera et al 1999 | MMC + tegafur | 76 | 56 | 0.04 | ? |
Control | 72 | 36 |
Abbreviations: FU, fluorouracil; LT, leucovorin; MMC, mitomycin.